<?xml version="1.0" encoding="UTF-8"?>
<ref id="B78-pharmaceutics-12-00171">
 <label>78.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Latinovic</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Kuruppu</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Davis</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Le</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Heredia</surname>
    <given-names>A.</given-names>
   </name>
  </person-group>
  <article-title>Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc</article-title>
  <source>Clin. Med. Ther.</source>
  <year>2009</year>
  <volume>1</volume>
  <fpage>CMT.S2365</fpage>
  <pub-id pub-id-type="doi">10.4137/CMT.S2365</pub-id>
  <?supplied-pmid 19920876?>
  <pub-id pub-id-type="pmid">19920876</pub-id>
 </element-citation>
</ref>
